ClinicalTrials.gg
RecruitingNCT07106996Updated Aug 6, 2025

Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome

An Early Phase 1 interventional study of red yeast rice,RYR in Polycystic Ovary Syndrome (PCOS), sponsored by Sichuan Provincial People's Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Sichuan Provincial People's Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Polycystic Ovary Syndrome with a site in China — 29 open to participants now, 33 under way, none of them phase 3. Polycystic Ovary Syndrome · China.

Planned enrollment
49th of 86
90 · median 100
Started
2025
with 9 others
Phase 1
3 of 107
2 open now
Primary completion
2026-06
later than 15 of 32 live
Registered
94th of 107
by date

Among the 107 studies in Polycystic Ovary Syndrome with a site in China, this one is the 49th largest by planned enrollment of the 86 interventional ones that give a count, is one of 10 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 15 of the 32 other live ones, and was the 94th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

29 of the 107 studies in Polycystic Ovary Syndrome with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Polycystic Ovary Syndrome with a site in China, or all of them as a file.
02

Study summary

The aim of this study is to elucidate the effects of red yeast rice on the improvement of symptoms in patients with polycystic ovary syndrome(PCOS), and to analyze the dose-response relationship between intestinal microbiota and its metabolite, hydroxyindole, and clinical indicators of PCOS.

The main questions it aims to answer are:

How effective is red yeast rice in treating PCOS? Does the indole metabolic pathway of gut microbiota play a crucial role in the improvement of PCOS symptoms by red yeast rice? Participants will take 6 grams of red yeast rice daily for 6 months, and records will be kept of their PCOS clinical symptoms and indicators before the intervention, at the 3rd month post-intervention, and at the 6th month post-intervention. Additionally, biological samples from feces and serum will be collected at these time points.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)

Keywords

  • Polycystic ovary syndrome
  • red yeast rice
  • intestinal microbiota
  • indole metabolism
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-40 years old
  • Meeting the Rotterdam criteria (at least two of the following):
  • Anovulation or oligo-ovulation
  • Clinical evidence of hyperandrogenism or hyperandrogenemia
  • Ultrasound findings indicating polycystic ovarian morphology (defined as at least 12 follicles measuring 2-9 mm in diameter and/or an ovarian volume >10 mL [length × width × thickness / 2] in one ovary)
  • Subjects who have been fully informed of the study procedures and related risks, and voluntarily agree to participate

Exclusion criteria

Exclusion Criteria

  • Pregnant women (confirmed via urine/serum hCG)
  • Patients with concomitant infectious diseases or severe dysfunction of multiple systemic organs
  • Patients who have taken antibiotics or other drugs (such as probiotics, prebiotics, etc.) that can alter the composition of intestinal flora within 3 months before enrollment
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Accept the red yeast rice intervention group

    Red yeast rice (RYR), a fermented product that has both medicinal and edible properties, is one of the traditional Chinese medicines used in the treatment of metabolic diseases. The main components of red yeast rice include monacolins, monacolin K, red yeast rice pigments, ergosterol, stigmasterol, β-sitosterol, daucosterol.

    Drug: red yeast rice,RYR

Interventions

  • Drugred yeast rice,RYR

    Participants will take 6 grams of red yeast rice daily for 6 months.

06

What researchers measure

Primary outcomes

  1. inflammatory marker IL18 [pg/ml]

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  2. inflammatory marker IL1β [pg/ml]

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  3. testosterone (nmol/l)

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  4. Follicle - Stimulating Hormone (mIU/mL)

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  5. Luteinizing Hormone (mIU/mL)

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  6. Estradiol (pmol/l)

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  7. Progesterone (ng/mL)

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  8. Prolactin (ng/mL)

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  9. follicles number

    The number of follicles in each ovary of each participant will be determined by ultrasonography.

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  10. ovarian volume(Length x Width x Thickness/2,ml)

    The size of each ovary in each participant will be determined by ultrasonography.

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  11. Follicle diameter(mm)

    The diameter of the follicles will be determined by ultrasonography.

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  12. Hydroxyindole concentration

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

Secondary outcomes

  1. Body-mass-index (BMI)

    BMI measured with the formula BMI=weight \[kg\]/height² \[m\]

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

  2. waist-to-hip ratio

    Calculated with the formula: waist circumference/hip circumference

    Time frame: Baseline, the 3rd month and the 6th month after the intervention

Other outcomes

  1. The metagenomics of fecal samples

    Total DNA of fecal samples is extracted by CTAB method.

    Time frame: before the intervention, at the 3rd month and the 6th month after the intervention

  2. Non-targeted metabolomic analysis of fecal and serum samples

    Fecal and serum samples were subjected to untargeted metabolomic detection using LC-MS/MS with an Agilent UHPLC system coupled to an Agilent 6538 UHD and Accurate-Mass Q-TOF mass spectrometer. Metabolites in the samples were separated, identified, and their information was acquired. Univariate and multivariate analyses were performed on the metabolites to screen for significantly differential metabolites before and after treatment.

    Time frame: before the intervention, at the 3rd month and the 6th month after the intervention

07

Study locations

1 of 1 sites recruiting
  • Lishui Hospital of Traditional Chinese Medicine
    Lishui, Zhejiang 323000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.

Of 27 phase 1 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 147. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Aug 6, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Aug 1, 2026
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07106996
Lead sponsor
Sichuan Provincial People's Hospital
Collaborators
Lishui Hospital of Traditional Chinese Medicine
Responsible party
Zhengwei Wan (professor, Sichuan Provincial People's Hospital) — Principal investigator
First posted
Aug 6, 2025
Start date
Jul 28, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Aug 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion